Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.815 -0.085 (-1.73%)
Streaming Delayed Price Updated: 3:42 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
Via AB Newswire
News headline image
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
Via AB Newswire
News headline image
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Participate in Upcoming Investor Conferences
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Completes Redomiciliation to the United States
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration 
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
atai Life Sciences Awarded Grant from the National Institutes of Health
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder 
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.